Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Prostate Cancer

Free Subscription Articles published in Proc Natl Acad Sci U S A Retrieve available abstracts of 23 articles: HTML format

Single Articles

December 2025
1. ERSOY-FAZLIOGLU B, Lingadahalli S, Altintas UB, Cingoz A, et al
   Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer.
   Proc Natl Acad Sci U S A. 2025;122:e2500327122.
   PubMed     Abstract available
   
   
   November 2025
2. ZHANG X, Yang Y, Zou H, Cai D, et al
   Circadian regulator REV-ERBalpha is a master regulator of tumor lineage plasticity and an effective therapeutic target.
   Proc Natl Acad Sci U S A. 2025;122:e2513468122.
   PubMed     Abstract available
   
   
   October 2025
3. YUAN S, Ming DJ, He J, Liu MY, et al
   A PHF19-YTHDC1 condensate switches EZH2-mediated gene suppression to activation for prostate cancer progression.
   Proc Natl Acad Sci U S A. 2025;122:e2510386122.
   PubMed     Abstract available
   
   
   
4. XIE J, Shen K, Liang W, Kuang Z, et al
   Protein disulfide isomerases regulate androgen receptor stability and promote prostate cancer cell growth and survival.
   Proc Natl Acad Sci U S A. 2025;122:e2509222122.
   PubMed     Abstract available
   
   
   September 2025
5. CHOWDHURY SR, Parikh CN, Kaur AN, DeMarco KD, et al
   PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors.
   Proc Natl Acad Sci U S A. 2025;122:e2514948122.
   PubMed     Abstract available
   
   
   
6. CHO H, Zhang Y, Tien JC, Mannan R, et al
   Cellular cartography reveals mouse prostate organization and determinants of castration resistance.
   Proc Natl Acad Sci U S A. 2025;122:e2427116122.
   PubMed     Abstract available
   
   
   July 2025
7. 
   Retraction for Kundu et al., Selective neutralization of IL-12 p40 monomer induces death in prostate cancer cells via IL-12-IFN-gamma.
   Proc Natl Acad Sci U S A. 2025;122:e2516531122.
   PubMed    
   
   
   
8. HE D, Zhang L, Yu L, Zhang Y, et al
   Fine structural design of 3betaHSD1 inhibitors for prostate cancer therapy.
   Proc Natl Acad Sci U S A. 2025;122:e2422267122.
   PubMed     Abstract available
   
   
   
9. SUSHENTSEV N, Hamm G, Manavaki R, McLean MA, et al
   Spatial metabolomics informs the use of clinical imaging for improved detection of cribriform prostate cancer.
   Proc Natl Acad Sci U S A. 2025;122:e2502423122.
   PubMed     Abstract available
   
   
   June 2025
10. PAPPAS K, Ferrari M, Smith P, Nandakumar S, et al
    BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex function.
    Proc Natl Acad Sci U S A. 2025;122:e2426743122.
    PubMed     Abstract available
    
    
    April 2025
11. 
    Correction for Pitzen et al., Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2025;122:e2504762122.
    PubMed    
    
    
    March 2025
12. LEE J, Park J, Hur Y, Um D, et al
    ETV5 reduces androgen receptor expression and induces neural stem-like properties during neuroendocrine prostate cancer development.
    Proc Natl Acad Sci U S A. 2025;122:e2420313122.
    PubMed     Abstract available
    
    
    February 2025
13. PITZEN SP, Rudenick AN, Qiu Y, Zhang W, et al
    Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2025;122:e2415308122.
    PubMed     Abstract available
    
    
    December 2024
14. VARUZHANYAN G, Chen CC, Freeland J, He T, et al
    PGC-1alpha drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity.
    Proc Natl Acad Sci U S A. 2024;121:e2416882121.
    PubMed     Abstract available
    
    
    November 2024
15. KOHRT SE, Novak EJ, Tapadar S, Wu B, et al
    Small-molecule disruption of androgen receptor-dependent chromatin clusters.
    Proc Natl Acad Sci U S A. 2024;121:e2406239121.
    PubMed     Abstract available
    
    
    October 2024
16. WANG Z, Yu H, Bao W, Qu M, et al
    Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics.
    Proc Natl Acad Sci U S A. 2024;121:e2402741121.
    PubMed     Abstract available
    
    
    September 2024
17. SU XA, Stopsack KH, Schmidt DR, Ma D, et al
    RAD21 promotes oncogenesis and lethal progression of prostate cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2405543121.
    PubMed     Abstract available
    
    
    August 2024
18. YU G, Corn PG, Mak CSL, Liang X, et al
    Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization.
    Proc Natl Acad Sci U S A. 2024;121:e2402903121.
    PubMed     Abstract available
    
    
    July 2024
19. PORNOUR M, Jeon HY, Ryu H, Khadka S, et al
    USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity.
    Proc Natl Acad Sci U S A. 2024;121:e2403331121.
    PubMed     Abstract available
    
    
    
20. ZAIDI S, Park J, Chan JM, Roudier MP, et al
    Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.
    Proc Natl Acad Sci U S A. 2024;121:e2322203121.
    PubMed     Abstract available
    
    
    April 2024
21. HE T, Cheng C, Qiao Y, Cho H, et al
    Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2322563121.
    PubMed     Abstract available
    
    
    December 2023
22. SUSHENTSEV N, Hamm G, Richings J, McLean MA, et al
    Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence.
    Proc Natl Acad Sci U S A. 2023;120:e2312261120.
    PubMed     Abstract available
    
    
    November 2023
23. MAJI S, Pradhan AK, Kumar A, Bhoopathi P, et al
    MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis.
    Proc Natl Acad Sci U S A. 2023;120:e2307094120.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.